Concepedia

Richard Yu

RY

Statistics

Publications

16

Citations

1.3K

H-Index

14

Active since

2001

Affiliations

Novartis (United States)(Current)

The University of Texas MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center

Novartis (Switzerland)

Royal Hobart Hospital

Richard Yu is an author at Novartis (United States) specializing in medicine, oncology, and urology.

Top concepts

Publications per year

2001–2017

16

Publications

16

Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

Jörge E. Cortes, Michele Baccarani, François Guilhot et al. · Journal of Clinical Oncology · 2009 · 285 citations · Full text

Diagnostic Accuracy of Urine Dipsticks for Detection of Albuminuria in the General Community

S. L. White, Richard Yu, Jonathan C. Craig et al. · American Journal of Kidney Diseases · 2011 · 219 citations

, , +11

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Byoung Chul Cho, Dong‐Wan Kim, Alessandra Bearz et al. · Journal of Thoracic Oncology · 2017 · 169 citations · Full text

, , +10

Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma

Robert J. Motzer, Robert J. Amato, Mary B. Todd et al. · Investigational New Drugs · 2003 · 153 citations

, , +5

Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma

Robert J. Motzer, Ashok Rakhit, Michelle S. Ginsberg et al. · Journal of Clinical Oncology · 2001 · 101 citations

1–5 of 16